Lineage Cell Therapeutics Provides Shareholder Update
Lineage Cell Therapeutics, Inc. (LCTX)
Company Research
Source: Business Wire
CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cellular therapies for unmet medical needs, today provided a year-end review and an outline of clinical and business plans for 2020.To Our Shareholders,As we conclude 2019, we want to provide clarity on what our shareholders can expect from Lineage next year. Our objective for 2019 was to establish a foundation from which we could become a leading cell therapy company. Our greater goal is to usher in a new branch of medicine, based on transplanting intact cells into the body to restore activity lost to aging, injury, or disease, which we believe is the best path to long-term success. This year-long campaign required us to make major changes in three areas. One, we expanded our product portfolio by combining three complementary clinical-stage assets under one roof. Two, we sold or stopped non-core activities, which significantly
Show less
Read more
Impact Snapshot
Event Time:
LCTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LCTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LCTX alerts
High impacting Lineage Cell Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LCTX
News
- Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering [Yahoo! Finance]Yahoo! Finance
- Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct OfferingBusiness Wire
- Lineage Cell (LCTX) Loses -26.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner [Yahoo! Finance]Yahoo! Finance
- Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering [Yahoo! Finance]Yahoo! Finance
- Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct OfferingBusiness Wire